ClinicalTrials.gg
RecruitingNCT07048262Updated Oct 19, 2026

Dose Range Finding, Efficacy, and Safety Study of Nebulized CSL787 in Adults With Non-cystic Fibrosis Bronchiectasis (NCFB)

A Phase 2 interventional study of CSL787 and Placebo in Non-cystic Fibrosis Bronchiectasis, sponsored by CSL Behring. Recruiting at 13 sites in 2 countries. Open to participants aged 18 Years to 85 Years. Per ClinicalTrials.gov, last updated 2026-10-19.

Sponsored by CSL Behring (part of CSL Limited) · Phase 2, Interventional, and Treatment

From the registry’s dates

  • Started Sep 2025; still recruiting 1 year 2 months later.
Updated Oct 19, 2026Primary completion movedStudy completion moved+3 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
180
Allocation
Randomized
Ages
18 Years to 85 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 16 studies in Inflammation with a site in Japan — 3 open to participants now, 4 under way, none of them phase 3. Inflammation · Japan.

Planned enrollment
6th of 13
180 · median 120
Started
2025
the only one that year
Phase 2
5 of 16
1 open now
Registered
16th of 16
by date
Lead sponsor
1 of 16
CSL Behring

Among the 16 studies in Inflammation with a site in Japan, this one is the 6th largest by planned enrollment of the 13 interventional ones that give a count, is the only one that started in 2025, is one of 5 in phase 2, and was the 16th registered.

Inflammation

3,541 studies on the registry are indexed under Inflammation; 646 are open to participants now.

Browse Inflammation studies →

Open to participants now

3 of the 16 studies in Inflammation with a site in Japan are open now. Recruiting first, the newest first:

All 3 open studies →

A study can be open while its sites in Japan have not opened yet or have stopped. Only those recruiting at a site in Japan →

Who these studies take

Of the 461 Inflammation studies recruiting now, 174 (38%) set no upper age limit and 206 (45%) stop at 75 or younger; 56 take children under 18; 165 take healthy volunteers.

This study: 18 Years to 85 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 16 studies in Inflammation with a site in Japan, or all of them as a file.
02

Study summary

This study is a proof-of-concept phase 2b, multicenter, randomized, double-blind, placebo-controlled, parallel-group, dose selection study designed to explore the efficacy, safety, and tolerability of 2 active treatment regimens of CSL787 (human normal immunoglobulin G [IgG] inhalation solution) compared with placebo over 52 weeks.

The primary aim of the study is to characterize the overall effect of CSL787 as well as the dose response of 2 active treatment regimens of inhaled CSL787 administered to participants with NCFB toward prolonging the time to first (TTF) exacerbation.

03

Conditions studied

  • Non-cystic Fibrosis Bronchiectasis

Browse trials for

Keywords

  • Chronic respiratory disease
  • Inflammation
  • Chronic bacterial infection
04

Who can participate

The criteria were revised on the registry on Oct 19, 2026. See what changed

Ages eligible
18 Years to 85 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Adult between the ages of 18 to 85 years
  • Capable of spontaneous sputum production at Screening.
  • Primary diagnosis of NCFB confirmed by chest computed tomography (CT) scan, where bronchiectasis has been documented by a radiologist. Diagnosis in the medical records based on documented historical scans is acceptable if the chest CT, scan confirming the participant's NCFB diagnosis was performed within 12 months before enrollment. Participants for whom no chest CT scan results are available within the previous 12 months will undergo a chest CT scan during the Screening Period.
  • Exacerbation history within the previous 1 year defined as one of the following:
  • greater than or equal (≥) 2 documented exacerbations requiring oral and/or intravenous (IV) antibiotic therapy to treat a pulmonary infection.

OR

  • 1 documented exacerbation requiring oral and/or IV antibiotic therapy to treat a pulmonary infection and a St. George's Respiratory Questionnaire (SGRQ) Symptoms score of greater than (>) 40 at Screening.
  • Note: Other medications to treat NCFB such as: oral macrolides, or dipeptidyl peptidase-1 (DPP-1) inhibitors are allowed, provided ≥ 1 historical exacerbation occurred while on the medication for ≥ 3 months at a stable dose.
  • Postbronchodilator percent predicted (FEV1%) > 35% and forced expiratory volume in 1 second (FEV1) ≥ 1 L obtained in accordance with American Thoracic Society (ATS) / European Respiratory Society (ERS) standards for spirometry during Screening and at Baseline on Day 1.

Exclusion criteria

Exclusion Criteria:

  • History of severe or uncontrolled asthma, or bronchospasm in response to inhaled therapies including inhaled antibiotics.
  • Known or suspected , or other severe reactions, to the product (IP), to any of the IP, or to other immunoglobulins.
  • Primary diagnosis of other pulmonary disorders, including (COPD), asthma, or diffuse panbronchiolitis (DPB), as determined by the investigator.
  • Use of oral, IV, or inhaled antibiotic therapy to treat a pulmonary exacerbation or any other condition within 4 weeks before Baseline measurements on Day 1.
Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

FEV1

From a breathing test (spirometry): how much air you can blow out in the first second. Often given as a percentage of what is expected for your age, height and sex.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

COPD

Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
180 participants (estimated)

Study arms

  • Experimental
    CSL787 High Dose

    Participants in this arm will receive a high dose of CSL787.

    Biological: CSL787 · Device: Nebulizer

  • Experimental
    CSL787 Low Dose

    Participants in this arm will receive a low dose of CSL787.

    Biological: CSL787 · Device: Nebulizer

  • Placebo comparator
    Placebo

    Participants in this arm will receive placebo.

    Drug: Placebo · Device: Nebulizer

Interventions

  • BiologicalCSL787

    CSL787 high or low doses once daily (QD) will be administered via inhalation over a period of 52 weeks.

  • DrugPlacebo

    Participants will receive a matching volume of placebo QD over a period of 52 weeks.

  • DeviceNebulizer

    The nebulizer is a CE-marked device.

06

What researchers measure

Primary outcomes

  1. Time to first (TTF) Exacerbation

    TTF exacerbation, where an exacerbation is defined as a deterioration in ≥ 3 of the following symptoms for ≥ 48 hours: cough; sputum volume and / or consistency; sputum purulence; breathlessness and / or exercise tolerance; fatigue and / or malaise; hemoptysis AND a clinician determines that antibiotic therapy is required.

    Time frame: Up to Week 52

Secondary outcomes

  1. Number of exacerbations over the Treatment and Observation Period

    Time frame: Up to Week 52

  2. Number of Participants Achieving a Minimally Clinically Important Difference (MCID) in the Quality of Life-Bronchiectasis (QoL-B) Respiratory Symptoms Scale

    The QoL-B questionnaire is a self-administered measure assessing symptoms, functioning, and health-related quality of life for patients with NCFB. This questionnaire contains 37 items on 8 different scales (Respiratory symptoms, Physical, Role, Emotional and Social Functioning, Vitality, Health Perceptions, and Treatment Burden). For each scale, scores are standardized on a 0-to-100-point scale; higher scores indicate better health-related quality of life.

    Time frame: Up to Week 52

  3. Percentage of Participants Achieving a MCID in the QoL-B Respiratory Symptoms Scale

    The QoL-B questionnaire is a self-administered measure assessing symptoms, functioning, and health-related quality of life for patients with NCFB. This questionnaire contains 37 items on 8 different scales (Respiratory symptoms, Physical, Role, Emotional and Social Functioning, Vitality, Health Perceptions, and Treatment Burden). For each scale, scores are standardized on a 0-to-100-point scale; higher scores indicate better health-related quality of life.

    Time frame: Up to Week 52

  4. Change From Baseline in QoL-B Respiratory Symptoms Scale

    The QoL-B questionnaire is a self-administered measure assessing symptoms, functioning, and health-related quality of life for patients with NCFB. This questionnaire contains 37 items on 8 different scales (Respiratory symptoms, Physical, Role, Emotional and Social Functioning, Vitality, Health Perceptions, and Treatment Burden). For each scale, scores are standardized on a 0-to-100-point scale; higher scores indicate better health-related quality of life.

    Time frame: Baseline to Week 52

  5. Change From Baseline in Total Colony-forming Unit (CFUs) for Pathogenic Bacteria Isolated from Sputum

    Time frame: Baseline up to Week 52

  6. Number of Participants with Treatment-emergent Adverse events (TEAEs) and Serious Adverse Events (SAEs)

    Time frame: Up to Week 56

  7. Percentage of Participants with TEAEs and SAEs

    Time frame: Up to Week 56

07

Study locations

13 of 13 sites recruiting
  • The Prince Charles Hospital
    Queensland, Australia
    Recruiting
  • Westmead Hospital
    Westmead, Australia
    Recruiting
  • Fukuoka University Chikushi Hopsital
    Chikushino-shi, Japan
    Recruiting
  • Kyusho Central Hospital of the Mutual Aid Association of Public School Teachers
    Fukuoka, Japan
    Recruiting
  • Ibaraki Prefectural Central Hospital
    Ibaraki, Japan
    Recruiting
  • Kazunori Tobino Iizuka Hospital
    Iizuka-shi, Japan
    Recruiting
  • National Hospital Organization Minami Kyoto Hospital
    Kyoto, Japan
    Recruiting
  • Matsusaka Municipal Hospital
    Mie, Japan
    Recruiting
  • National Hospital Organization Kinki Chuo Chest Medical Center
    Osaka, Japan
    Recruiting
  • Shimonoseki City Hospital
    Shimonoseki-shi, Japan
    Recruiting
  • Japan Anti-Tuberculosis Association, Fukujuji Hospital
    Tokyo, Japan
    Recruiting
  • Keio University Hospital
    Tokyo, Japan
    Recruiting
  • National Hospital Organization Mie Chuo Medical Center
    Tsu, Japan
    Recruiting
08

References and documents

Individual participant data

Plan to share: Yes — CSL will consider on a case-by-case basis requests to share Individual Patient Data (IPD) with external bona-fide, qualified scientific and medical researchers. For information on the process and requirements for submitting a voluntary data sharing request for IPD, please contact CSL at clinicaltrials@cslbehring.com.

Supporting information: Study protocol, Statistical analysis plan

Time frame: Requests for IPD will generally be considered once review by major regulatory authorities (i.e. FDA, EMA) is complete and the primary publication is available.

Access criteria: Proposed research should seek to answer a previously unanswered important medical or scientific question. Applicable country specific privacy and other laws and regulations will be considered and may prevent sharing of IPD. If the request is approved and the researcher has executed an appropriate data sharing agreement, IPD that has been appropriately anonymized will be available.

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Sep 2025 (actual). Primary completion is estimated for May 2029, 44 months after the start.

Of 36 industry-sponsored phase 2 interventional studies under Inflammation, half reached primary completion within 17 months of starting (the median), counting those still running; a quarter within 10 and three quarters within 26. This study's planned 44 months is above that.

Counting every sponsor, half of 149 studies reached it within 29 months; a quarter within 16 and three quarters within 56.

Since we started tracking on Sep 25, 2026, the dates moved once, on Oct 19, 2026: primary completion Feb 2028 → May 2029 and completion Mar 2028 → Jun 2029.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Jun 24, 2025
First posted
Jul 2, 2025
StartActual
Sep 3, 2025
Primary completionEst.
May 6, 2029was Feb 2028
CompletionEst.
Jun 6, 2029was Mar 2028
Last update
Oct 19, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Primary completion
Feb 28, 2028→May 6, 2029
Oct 19, 2026
Study completion
Mar 28, 2028→Jun 6, 2029
Oct 19, 2026
Enrollment
450→180
Oct 19, 2026
Eligibility
6 inclusion criteria edited, 1 added; 4 exclusion criteria edited
What changed in the criteria
Inclusion criteria
  • AddedCapable of spontaneous sputum production at Screening.
  • EditedPrimary diagnosis of NCFB confirmed by chest computed tomography (CT) scan, where bronchiectasis has been documented by a radiologist. Diagnosis in the medical records based on documented historical scans is acceptable if the chest CT, scan confirming the participant's NCFB diagnosis was performed within 12 months before enrollment. Participants for whom no chest CT scan results are available within the previous 12 months will undergo a chest CT scan during the Screening Period.
  • EditedExacerbation history within the previous 1 year defined as either 1one of the following:
  • Edited>=greater than or equal (≥) 2 documented exacerbations requiring oral and/or intravenous (IV) antibiotic therapy to treat a pulmonary infection.
  • Edited1 documented exacerbation requiring oral and/or IV antibiotic therapy to treat a pulmonary infection and a St. George's Respiratory Questionnaire (SGRQ) Symptoms score of greater than (>) 40 at Screening.
  • EditedNote: Other medications to treat NCFB such as: oral macrolides, or dipeptidyl peptidase-1 (DPP-1) inhibitors are allowed, provided >=≥ 1 historical exacerbation occurred while on the medication for >=≥ 3 months at a stable dose.
  • EditedPostbronchodilator percentage of thepercent predicted normal forced expiratory volume in 1 second of expiration [(FEV1% predicted]) > 35% and forced expiratory volume in 1 second (FEV1) >=≥ 1 liter (L) obtained in accordance with American Thoracic Society (ATS) / European Respiratory Society (ERS) standards for spirometry during Screening and at Baseline on Day 1.
Exclusion criteria
  • EditedHistory of severe or uncontrolled asthma, or bronchospasm in response to inhaled therapies including inhaled antibiotics.
  • EditedKnown or suspected hypersensitivity, or other severe reactions, to the investigational product (IP), to any excipients of the IP, or to other immunoglobulinimmunoglobulins.
  • EditedPrimary diagnosis of other pulmonary disorders, including chronic obstructive pulmonary disease (COPD), asthma, or, diffuse panbronchiolitis (DPB), as determined by the investigator.
  • ChangedBefore Pulmonary exacerbation requiring antibiotic therapy within the 4 weeks before Baseline.Now Use of oral, IV, or inhaled antibiotic therapy to treat a pulmonary exacerbation or any other condition within 4 weeks before Baseline measurements on Day 1.
Oct 19, 2026
Primary outcomes
1 time frame changed, 1 description edited
What changed in the outcomes
  • Time frameTime to first (TTF) ExacerbationUp to Month 12 → Up to Week 52
  • DescriptionTime to first (TTF) Exacerbation: how it is measured was reworded
Oct 19, 2026
Secondary outcomes
3 edited, 4 time frame changed
What changed in the outcomes
  • EditedNumber of Participants Achieving a Minimally Clinically Important Difference (MCID) in the Quality of Life-Bronchiectasis (QoL-B) Respiratory Symptoms ScaleTime frame: Up to Month 12 → Up to Week 52
  • EditedPercentage of Participants Achieving a Clinically Important DifferenceMCID in the QoL-B Respiratory Symptoms ScaleTime frame: Up to Month 12 → Up to Week 52
  • ChangedBefore Annualized Exacerbation Rate (AER) (Exacerbation Event Rate Per-participant Year)Now Number of exacerbations over the Treatment and Observation PeriodTime frame: Up to Month 12 → Up to Week 52
  • Time frameChange From Baseline in QoL-B Respiratory Symptoms ScaleFrom Baseline to Months 6 and 12 → Baseline to Week 52
  • Time frameChange From Baseline in Total Colony-forming Unit (CFUs) for Pathogenic Bacteria Isolated from SputumFrom Baseline to Month 1 → Baseline up to Week 52
  • Time frameNumber of Participants with Treatment-emergent Adverse events (TEAEs) and Serious Adverse Events (SAEs)Up to Month 13 → Up to Week 56
  • Time framePercentage of Participants with TEAEs and SAEsUp to Month 13 → Up to Week 56
Oct 19, 2026
Show all 1 update
  1. Oct 19, 2026
    Primary completion Feb 28, 2028→May 6, 2029
    Study completion Mar 28, 2028→Jun 6, 2029
    Enrollment 450→180
    Eligibility 6 inclusion criteria edited, 1 added; 4 exclusion criteria edited
    What changed in the criteria
    Inclusion criteria
    • AddedCapable of spontaneous sputum production at Screening.
    • EditedPrimary diagnosis of NCFB confirmed by chest computed tomography (CT) scan, where bronchiectasis has been documented by a radiologist. Diagnosis in the medical records based on documented historical scans is acceptable if the chest CT, scan confirming the participant's NCFB diagnosis was performed within 12 months before enrollment. Participants for whom no chest CT scan results are available within the previous 12 months will undergo a chest CT scan during the Screening Period.
    • EditedExacerbation history within the previous 1 year defined as either 1one of the following:
    • Edited>=greater than or equal (≥) 2 documented exacerbations requiring oral and/or intravenous (IV) antibiotic therapy to treat a pulmonary infection.
    • Edited1 documented exacerbation requiring oral and/or IV antibiotic therapy to treat a pulmonary infection and a St. George's Respiratory Questionnaire (SGRQ) Symptoms score of greater than (>) 40 at Screening.
    • EditedNote: Other medications to treat NCFB such as: oral macrolides, or dipeptidyl peptidase-1 (DPP-1) inhibitors are allowed, provided >=≥ 1 historical exacerbation occurred while on the medication for >=≥ 3 months at a stable dose.
    • EditedPostbronchodilator percentage of thepercent predicted normal forced expiratory volume in 1 second of expiration [(FEV1% predicted]) > 35% and forced expiratory volume in 1 second (FEV1) >=≥ 1 liter (L) obtained in accordance with American Thoracic Society (ATS) / European Respiratory Society (ERS) standards for spirometry during Screening and at Baseline on Day 1.
    Exclusion criteria
    • EditedHistory of severe or uncontrolled asthma, or bronchospasm in response to inhaled therapies including inhaled antibiotics.
    • EditedKnown or suspected hypersensitivity, or other severe reactions, to the investigational product (IP), to any excipients of the IP, or to other immunoglobulinimmunoglobulins.
    • EditedPrimary diagnosis of other pulmonary disorders, including chronic obstructive pulmonary disease (COPD), asthma, or, diffuse panbronchiolitis (DPB), as determined by the investigator.
    • ChangedBefore Pulmonary exacerbation requiring antibiotic therapy within the 4 weeks before Baseline.Now Use of oral, IV, or inhaled antibiotic therapy to treat a pulmonary exacerbation or any other condition within 4 weeks before Baseline measurements on Day 1.
    Primary outcomes 1 time frame changed, 1 description edited
    What changed in the outcomes
    • Time frameTime to first (TTF) ExacerbationUp to Month 12 → Up to Week 52
    • DescriptionTime to first (TTF) Exacerbation: how it is measured was reworded
    Secondary outcomes 3 edited, 4 time frame changed
    What changed in the outcomes
    • EditedNumber of Participants Achieving a Minimally Clinically Important Difference (MCID) in the Quality of Life-Bronchiectasis (QoL-B) Respiratory Symptoms ScaleTime frame: Up to Month 12 → Up to Week 52
    • EditedPercentage of Participants Achieving a Clinically Important DifferenceMCID in the QoL-B Respiratory Symptoms ScaleTime frame: Up to Month 12 → Up to Week 52
    • ChangedBefore Annualized Exacerbation Rate (AER) (Exacerbation Event Rate Per-participant Year)Now Number of exacerbations over the Treatment and Observation PeriodTime frame: Up to Month 12 → Up to Week 52
    • Time frameChange From Baseline in QoL-B Respiratory Symptoms ScaleFrom Baseline to Months 6 and 12 → Baseline to Week 52
    • Time frameChange From Baseline in Total Colony-forming Unit (CFUs) for Pathogenic Bacteria Isolated from SputumFrom Baseline to Month 1 → Baseline up to Week 52
    • Time frameNumber of Participants with Treatment-emergent Adverse events (TEAEs) and Serious Adverse Events (SAEs)Up to Month 13 → Up to Week 56
    • Time framePercentage of Participants with TEAEs and SAEsUp to Month 13 → Up to Week 56
    + 3 other changes: verification date, description and arm descriptions

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07048262
Lead sponsor
CSL Behring
Responsible party
Sponsor
First posted
Jul 2, 2025
Start date
Sep 3, 2025
Primary completion
May 6, 2029 (estimated)
Completion
Jun 6, 2029 (estimated)
Last update
Oct 19, 2026

Study contacts

Trial Registration Coordinator
Contact
clinicaltrials@cslbehring.com
+1 610-878-4697
Study Director
study director · CSL Behring

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
Yes
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Immunoglobulins, Intravenous

Start the discussion